Vaxign: a web-based vaccine target design program for reverse vaccinology  by Xiang, Zuoshuang & He, Yongqun
Procedia in Vaccinology 1 (2009) 23–29
Available online at www.sciencedirect.com
1877-282X © 2009 Published by Elsevier Ltd. 
doi:10.1016/j.provac.2009.07.005
Vaxign: a web-based vaccine target design program for reverse 
vaccinology 
Zuoshuang Xiang, Yongqun He* 
Unit for Laboratory Animal Medicine, Department of Microbiology and Immunology, and Center for Computational Medicine and Biology, 018 
ARF, 1150 W. Medical Center Dr., Ann Arbor, MI 48109, USA 
Abstract 
In the post-genomic era, strategies of vaccine development have progressed dramatically from traditional Pasteur’s principles of 
isolating, inactivating and injecting the causative agent of an infectious disease, to reverse vaccinology that starts from 
bioinformatics analysis of the genome information. Based on the reverse vaccinology strategy, we have developed a web-based 
vaccine design system called Vaxign (http://www.violinet.org/vaxign/). Vaxign predicts possible vaccine targets based on 
various vaccine design criteria using microbial genomic and protein sequences as input data. Major predicted features in the 
Vaxign pipeline include subcellular location of a protein, transmembrane domain, adhesion probability, sequence conservation 
among genomes, sequence similarity to host (human or mouse) proteome, and epitope binding to MHC class I and class II. This 
pipeline integrates both existing open source tools and internally developed programs with user-friendly web interfaces. A user 
can either query pre-computed Vaxign results for one protein sequence(s) from one genome(s) or perform dynamic analysis on 
input protein sequence(s). Vaxign has stored pre-computed results from more than 40 genomes from various pathogens (e.g., 
Brucella). The analysis results indicate that Vaxign specifically and sensitively predicts known vaccine targets and also provides 
new vaccine target candidates. Vaxign is part of the web-based system called Vaccine Investigation and Online Information 
Network (VIOLIN, http://www.violinet.org). Vaxign is a freely available program that facilitates vaccine researchers to 
efficiently design vaccine targets and develop vaccines using rationale reverse vaccinology.  
  
© 2009 Elsevier B.V.  
1. Introduction 
Traditional vaccine development follows Pasteur’s principles of isolating, inactivating and injecting the causative 
agent of an infectious disease. This approach has been successful in generation of effective vaccine products. One 
disadvantage of this strategy is that it takes long (typically 5-15 years) to identify valuable targets for vaccine 
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research. Reverse vaccinology begins with bioinformatics analysis of a whole genome. More than 700 microbial 
genomes have been sequenced and analyzed, which provide a foundation for scientists to develop vaccines using the 
reverse vaccinology. Reverse vaccinology shortens the period of vaccine target discovery and evaluation to 1-2 
years [1]. This new strategy also revolutionizes new vaccine development against pathogens for which the 
applications of Pasteur’s principles have failed.  
Rappuoli is credited to be the pioneer of reverse vaccinology [1, 2]. His group was the first to use reverse 
vaccinology for development of a vaccine against serogroup B Neisseria meningitidis (MenB), the major cause of 
sepsis and meningitis in children and young adults [2]. The complete MenB genome was screened using 
bioinformatic algorithms for open reading frames (ORFs) coding for putative surface-exposed or secreted proteins, 
which are susceptible to antibody recognition and therefore the most suitable vaccine candidates. Out of 
approximately 600 novel vaccine candidates, 350 were expressed in Escherichia coli, and 28 were found to elicit 
protective immunity. It took less than 18 months to identify more vaccine candidates in MenB than had been 
discovered during the past 40 years by conventional methods [2]. The concept of reverse vaccinology has also 
successfully been applied to many other pathogens [1], including Bacillus anthracis, Chlamydia pneumoniae, 
Porphyromonas gingivalis, and Streptococcus pneumoniae.  
The reverse vaccinology technology has progressed dramatically since it was invented nine years ago. In addition 
to prediction of secreted and/or outer membrane proteins, vaccine researchers may also consider transmembrane 
helices and sequence similarity to host genomes. Vaccine targets conserved among all or most virulent pathogens 
are preferred. Epitope prediction from protective antigens is critical for development of epitope vaccines. Although 
many individual software programs are available to help vaccine target prediction [3-10], they are usually 
individually developed for different purposes and contain disparate data formats and programming settings. This 
makes tool and data integration difficult. Successful use of these tools often requires local installation, command 
line execution, and heavy computational power. Many tools are not optimized for high throughput data processing. 
To address these problems and help the vaccine R&D community, we have developed the first web-based, 
publically available vaccine design system called Vaxign (http://www.violinet.org/vaxign). 
2. Methods 
Vaxign software components for vaccine target prediction: Vaxign integrates open source tools and internally 
developed programs with user-friendly web interfaces. The input data for Vaxign execution are amino acid 
sequences from one protein(s) or whole genomes. This Vaxign pipeline includes the following components (Fig. 1):  
(1) Prediction of subcellular localization. Vaxign predicts different subcellular locations using optimized 
PSORTb 2.0 that has a measured overall precision of 96% [3].  
(2) Transmembrane helix prediction. The topology analysis is performed using optimized HMMTOP based on a 
general hidden Markov model (HMM) decoding algorithm [4].  
(3) Calculation of adhesin probability. Adhesin probability is predicted using optimized SPAAN that has 
sensitivity of 89% and specificity of 100% on a defined test set [5]. The default cut off is 0.51.  
(4) Protein conservation among different genomes. This program is to find conserved sequences among more 
than one genome. OrthoMCL is applied to calculate the homology between different sequences [6]. The E-value of 
10-5 is set as the default value. An internally developed reciprocal best fit method based on BLAST was also 
developed for result comparison.  
(5) Exclusion of sequences present in non-pathogenic strains. OrthoMCL is used to calculate the homology 
between predicted sequences and all proteins in a specified non-pathogenic strain genome(s) [6].  
(6) Comparison of sequence similarity between predicted proteins and host (human and/or mouse) proteome. 
OrthoMCL is customized for this purpose. 
(7) Prediction of MHC class I and class II binding epitopes. Vaxign uses an internally developed program 
Vaxitope to predict MHC class I and class II binding epitopes. Vaxitope is developed based on PSSM (Position 
Specific Scoring Matrix) motif prediction. The PSSMs for the prediction of peptide binders to MHC class I or II are 
calculated based on a position-based weighting method using the BLK2PSSM utility included in the BLIMPS 
package [7]. The data for generating the PSSMs came from known epitope data from the IEDB immune epitope 
database [11]. The P value for the predicted epitope binding to PSSMs is calculated by the MAST sequence 
homology search algorithm [12]. A receiver operating characteristic (ROC) curve and the values of the area under 
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the ROC Curve (AUC) were used to calculate the accuracy of the Vaxitope prediction [13]. For the AUC analysis, 
the epitope data from the IEDB immune epitope database [11] were used. A leave-one-out approach was applied to 
test if a known epitope can be predicted on the condition that this epitope is excluded in initial generation of PSSMs.  
(6) Protein functional analysis: Predicted proteins can be selected and automatically exported to the DAVID 
bioinformatics resources (http://david.abcc.ncifcrf.gov/) for function protein analysis.. 
Vaxign server and web implementation: Vaxign is implemented using a three-tier architecture built on two Dell 
Poweredge 2580 servers which run the Redhat Linux operating system (Redhat Enterprise Linux ES 5). Users can 
submit database or analysis queries through the web. These queries are then processed using PHP/HTML/SQL 
(middle-tier, application server based on Apache) against a MySQL (version 5.0) relational database (back-end, 
database server), or executed in runtime based on the Vaxign algorithm pipeline. The result of each query is then 
presented to the user in the web browser (Fig. 1). Two servers are scheduled to regularly backup each others’ data. 
Vaxign applications of vaccine target prediction: Microbial genomes and protein sequences were downloaded 
from NCBI RefSeq database or UniProt database.  
3. Results:  
The Vaxign algorithm for vaccine target prediction: The workflow of the Vaxign pipeline is shown in Fig. 1. The 
predicted features in Vaxign include protein subcellular location, transmembrane helices, adhesin probability, and 
sequence conservation among pathogen genomes, and sequence similarity to host (human and mouse) proteomes. 
Surface-exposed proteins such as secreted proteins and outer membrane proteins (especially adhesins) are ideal 
targets for vaccine development. Non-surface proteins such as cytoplasmic or inner membrane proteins, however, 
may not represent good targets for vaccine development due to lack of close contact with the host cells [1, 2]. It has 
been reported that 250 out of 600 
vaccine candidates from N. 
meningitidis B failed to be cloned 
and expressed due to the presence 
of more than one transmembrane 
spanning region [2]. Therefore, it 
might be prudent to ignore those 
proteins with multiple 
transmembrane spanning regions in 
the first place. The adhesion of 
microbial pathogens to host cells is 
mediated by adhesins. Adhesins are 
essential for bacterial colonization 
and survival and are possible 
targets for vaccine development. The conserved vaccine targets among different strains in one pathogen offer 
protection against these different strains. A vaccine candidate with similar sequence to the host (e.g., human or 
mouse) is likely to be a poor immunogen through epitope mimicry, or if an immune response is triggered, cause 
autoimmunity in the host. These aspects are considered in the Vaxign prediction pipeline (Fig. 1).  
Vaxign predicts both MHC class I and class II binding epitopes using Vaxitope we developed internally. 
Vaxitope predicts epitopes based on the Position Specific Scoring Matrix (PSSM), a type of scoring matrix used in 
protein similarity searches in which amino acid substitution scores are given separately for each position in a protein 
multiple sequence alignment. The strategy of using PSSMs for prediction of MHC Class I and II binding has proven 
effective in RANKPEP [8]. To evaluate the performance of Vaxitope, a receiver operating characteristic (ROC) 
curve [13] was generated using HLA A*0201 specific PSSM (Fig. 2). HLA A*0201 is one of the most studied HLA 
MHC Class I allele. According to the IEDB immune epitope database [11], 3216 epitopes are known to positively 
bind to this allele (as positive testing dataset), and 4826 epitopes cannot bind to this allele (as negative testing 
dataset). The positive HLA A*0201 aelles were used to calculate the True Positive Rate (Sensitivity). The negative 
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Fig. 1. The Vaxign algorithm pipeline. 
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alleles were used to calculate the False Postive Rate (1-Specificity) (Fig. 2). The value of the Area Under the ROC 
Curve (AUC) for the HLA A*0201 analysis using Vaxitope is 0.929. The ROC AUCs for other alleles are also 
calculated and provided in the Vaxign website for users' reference. Our 
studies show that Vaxitope is a very specific and sensitive method for MHC 
Class I and II binding epitope prediction. Different from RANKPEP, 
Vaxitope defines statistical P-values based on a random sequence model that 
assumes each position in a random sequence is generated according to the 
average letter frequencies of all sequences in the NCBI peptide non-
redundant database [12]. The P-value of 0.05 provides a cutoff with high and 
balanced sensitivity and specificity. Another unique feature in Vaxitope is 
that it integrates with other vaccine design components in Vaxign. For 
example, the input sequence of Vaxitope may come from those peptides that 
are part of an outer membrane protein and exposed outside the bacterial 
membrane (Fig. 3). These protein peptides are predicted by Vaxign and 
easily available as input data for Vaxitope. Vaxitope also allows genome-
wide query on different MHC host species.  
Fig. 3. Vaxign prediction of Brucella vaccine targets. (A) Selection of B. abortus strain 2308 as a seed genome. Different filter 
options are applied: only outer membrane proteins, maximum of one transmembrane helixes, minimal adhesion probability of 
0.51, having orthologs in three virulent Brucella strains, and no similarity to any human or mouse protens. (B) In total 17 proteins 
were predicted to meet selected criteria. (C) Detailed results for a particular protein (e.g., Omp2b). MHC Class I and II epitope 
prediction results are also available and can be further filtered. (D) Prediction of subcellular location of Omp2b fragments.  
Vaxign includes user-friendly web interface (Fig. 3). Two forms of Vaxign web query exist. A user can either 
query pre-computed Vaxign results for one protein sequence(s) from one genome(s) (Fig. 3).  The pre-computed 
Vaxign database currently contains prediction results from >40 genomes. Users can set up preferred query criteria 
using a simple query interface. The query of pre-computed Vaxign results is fast. A typical query involved in four 
genomes and all the steps as shown in our Brucella use case (Fig. 3) takes approximately 2-5 seconds. The other 
form is dynamic Vaxign analysis. It is similar to the pre-computed Vaxign except that a user is prompted to provide 
protein sequences using FASTA format for up to 300 proteins at one time. Vaxign predicts vaccine targets based on 
runtime execution. It takes approximately 30-60 seconds to execute all the steps in run time for one single protein. 
Therefore, it would take 150-300 minutes to finish analysis of 300 proteins. Once all steps are finished, the web link 
of the predicted results will be sent to a registered user through email. 
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Vaxign applications in vaccine target prediction: A list of 11 known protective antigens from four bacterial 
pathogen strains were chosen for Vaxign evaluation (Table 1). The predicted results were manually confirmed to be 
valid based on existing literature and database survey.  
Table 1. Analysis of protective antigens in bacterial pathogens using Vaxign. 
Pathogen Strains Protein Name (Accession #) 
Subcellular location 
(Prob.) 
Adhesin 
Prob. 
Trans-
membrane 
Helix  
References 
PorA (Q51240), Outer membrane (1) 0.66 0 
NspA (Q7DDM2) Outer membrane (1) 0.64 0 N.  meningitidis B
strain MC58 TbpB (Q9K0V0), Outer membrane (0.95) 0.84 0 
[14] 
CagA (Q9ZKW5) Outer membrane (0.95) 0.75 0 H. pylori strain J99
(Gram -) VacA (Q9ZLT1) Outer membrane (1) 0.98 1 [15] 
PagA (P13423) Extracellular (1) 0.80 0 
Sap (P49051), Cell wall (1) 0.78 0 
B. anthracis strain 
Ames Ancestor 
(Gram+) EA1 (P94217), Cell wall (1) 0.67 0 
[16] 
85A (NP_218321.1) Extracellular (1) 0.76 1 
85B (NP_216402.1) Extracellular (1) 0.74 1 
M. tuberculosis
strain H37Rv 
(Gram+) ESAT-6 (YP_178023.1) Extracellular (1) 0.86 0 
[17] 
Brucella is a facultative intracellular bacterium that causes chronic brucellosis in humans and animals. Brucellosis is 
the most common zoonotic disease with half a million new cases annually worldwide. No Brucella vaccine exists 
for human use. Vaxign was used to predict Brucella vaccine targets based on four Brucella genomes from four 
virulent Brucella strains in three Brucella species (Fig. 3). Only proteins conserved in all Brucella genomes are 
considered. In total, 2608 Brucella proteins are shared by four Brucella genomes. Among them are 30 conserved 
Brucella outer membrane proteins (OMP). Two proteins among the 30 outer membrane proteins have more than one 
transmembrane spanning region. These two proteins are not further considered. If only adhesins are considered, 10 
out of the 28 proteins have adhesin probability < 0.51 and hence discarded. One protein (BAB1_1944) has 
homology with human and mouse proteome. Therefore, only 17 proteins are predicted to meet all these criteria 
(Table 2). Among these 17 predicted Brucella vaccine targets, Omp25 (YP_414164.1) and Omp31 (YP_414995.1) 
have been found to be true protective Brucella antigens [18, 19]. The list of predicted targets also includes two 
group 2 porin proteins Omp2a (YP_414101.1) and Omp2b (YP_414102.1), two flagellar hook proteins FlgE 
(YP_419225.1) and FlgK (YP_419224.1), and two TonB-dependent receptor proteins BAB1_1367 and HemR. Their 
roles as protective antigens have not been studied but deserve further investigation.  
Table 2. Prediction of Brucella vaccine targets conversed in four sequenced Brucella genomes using Vaxign. 
Brucella Strains Total Gene No. OMP 
+ Trans-
membrane 
Helix (<2) 
+ Adhesin 
(Prob. >=0.51)
+ No Human 
Similarity 
+ No Mouse 
Similarity 
B. abortus strain 2308 3034 32 30 20 19 19 
B. abortus strain 9-941 3085 30 28 19 18 18 
B. melitensis strain16M 3198 32 30 21 20 20 
B. suis strain 1330 3271 34 32 20 20 20 
Conserved in 4 strains 2608 30 28 18 17 17 
4. Discussion 
Vaxign is a comprehensive web-based vaccine design software program freely available for the purpose of 
facilitating reverse vaccinology. Vaxign optimizes the conditions and performance of many public tools and 
developed new programs in a way optimal for performing high throughput data. The seamless integration makes 
Vaxign a user-friendly environment for reverse vaccinology study. Our results indicate that Vaxign specifically and 
sensitively predicts known vaccine targets and also provides new vaccine target candidates deserving further wet lab 
confirmation. Future directions of further Vaxign development include addition of other components such as 
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analysis of high throughput transcriptomic (e.g., DNA microarray and superarray) and proteomic data for vaccine 
target prediction. Literature mining of predicted vaccine targets will also help. Vaxign is part of the vaccine database 
and analysis resource VIOLIN [20]. The predicted vaccine targets from Vaxign will also integrate with those 
manually annotated vaccine data available in VIOLIN.  
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